Company / Return on Equity (ROE)
Xeris Biopharma Holdings, Inc. Return on Equity (ROE) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
4.0%
FY2025
5-year range
-363.5% / 4.0%
FY2021-FY2025
Trend
-
vs FY2024
Sector context
#47 of 190
Health Care
What the data says
Xeris Biopharma Holdings, Inc.'s return on equity (roe) of 4.0% is higher than 75% of companies in the Health Care sector (FY2025). Improved from -128.9% to 4.0% over the past 4 years.
Based on SEC 10-K filings.
4.0% in FY2025 with a 5-year CAGR of +274.0%. Top quartile in the Health Care sector.
Improved from -128.9% to 4.0% over the past 4 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +367.6pp
- 5-Year Change
- +274.0pp
- 10-Year Change
- -
Sector benchmark
Top 25% in Health CareTop 25% of 190This company 4.0% Sector average -50.3%
▼
+108.0% above sector average
Key checks
Key Insights
- Currently 54.4pp above the Health Care sector average.
Company context
Key Data Points
- Altman Z-Score -0.26 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 4.0% | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | -363.5% | -182.1% |
| FY2021 | -128.9% | +52.3% |
| FY2020 | -270.0% | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026